RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Whatever you do, don’t call it a festival. There’s no set schedule or events during the two-day gathering, warns Dave Shenkman, owner of Kite Connection on the Huntington Beach Pier and ...

Kite, Wičháȟpi Wóihanbleya (Dreamlike Star) (detail), 2024, multimedia environment with video, sound, stones, mirror, 21 min 16 sec. Photo: Shane Godfrey. Courtesy MIT List Visual Arts Center, ...

This leads investors to also remain optimistic about rising dividends in the future. Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

A subsidiary of Gilead Sciences, Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need.

The ABC Kite Fest returns for its 97th year with the classic kite showcase and kite contest, MossFest children’s concert, High Flyer VIP club and more "For almost 100 years, Austinites have ...